Not specifiedRegulatory Approvalcommercialmid-term

FDA Submission Update for ANDA220143 by Hetero Labs

Importance6/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/20/2026, 6:04:45 AM

Assessment confidence: 60% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of ANDA220143 by Hetero Labs signifies a potential shift in the competitive landscape of the generic drug market. Portfolio teams need to evaluate how this could affect pricing strategies and market dynamics in the relevant therapeutic area. Regulatory context from FDA (FDA AP — AFATINIB DIMALEATE (ORIG)) supports the near-term read. Assessment grounded in 19 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact of this submission on market dynamics and pricing strategies. The strongest clinical anchor is The Effect of Animated Videos and Therapeutic Play Methods on Emotional Expression, Fear and Anxiety in Children Aged 4-8 Years During the Throat Swab Procedure (ClinicalTrials.gov), moderate corpus alignment. In Not specified, 6 regulatory and 2 competitive items passed relevance filtering for Hetero Labs.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Approval for Enlicitide by Merck Sharp and Dohme (Humanexa Signals) — sponsor/company relevance (merck). Secondary pressure from FDA Approves Veklury as First Treatment for COVID-19. The submission indicates Hetero Labs is advancing in the generic drug market, potentially increasing competition in the relevant therapeutic area.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — AFATINIB DIMALEATE (ORIG) (FDA). Entity match (hetero labs); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The submission is under standard review, indicating no immediate regulatory concerns that would affect approval timelines.

Key Opportunities

Increased competition from Hetero Labs could lead to price reductions and shifts in market share among existing players, impacting revenue projections.
Upside for Hetero Labs may improve if Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities. (PubMed) delivers favorable follow-through.
Upside for Hetero Labs may improve if Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the potential impact of this submission on market dynamics and pricing strategies.

What Would Change This Assessment

This becomes more urgent if Monitor the review progress and any subsequent approvals or market entries related to ANDA220143.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — AFATINIB DIMALEATE (ORIG)
FDAhigh relevance
Entity match (hetero labs); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXCARBAZEPINE (SUPPL)
FDAhigh relevance
Entity match (hetero labs); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACYCLOVIR (SUPPL)
FDAhigh relevance
Entity match (hetero labs); Regulatory pathway relevance (nda)
FDA document
View source
Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates - 09/29/2026
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Register to make submissions to the MHRA
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

The Effect of Animated Videos and Therapeutic Play Methods on Emotional Expression, Fear and Anxiety in Children Aged 4-8 Years During the Throat Swab Procedure
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Characterization of Phenotypic and Genotypic Regressors for Imaging
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation of Postoperative Hearing Loss After Spinal Anesthesia for Elective Cesarean Section in Pregnant Women
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Characterization of Nociception Phenotype in Individuals With Intellectual Disability
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Approval for Enlicitide by Merck Sharp and Dohme
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalsmedium relevance
Moderate corpus alignment

Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Nanotechnology-mediated podocyte injury repair: mechanistic exploration and therapeutic prospects.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hetero Labs
therapeutic area competitors

Commercial impact

medium

Increased competition from Hetero Labs could lead to price reductions and shifts in market share among existing players, impacting revenue projections.

Regulatory impact

low

The submission is under standard review, indicating no immediate regulatory concerns that would affect approval timelines.

What to watch

Monitor the review progress and any subsequent approvals or market entries related to ANDA220143.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.